Insider · CIK 0001995657

Wapnick Pamela

Reports to the SEC for 1 company · EMERYVILLE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001995657

Forms 4 and 5

Insider transactions

16 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-08	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,911 sh	$1.16	−$2,213.702	206,580
2026-06-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,884 sh	$1.30	−$3,746.316	208,491
2026-04-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+24K sh	—	—	211,375
2026-04-01	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+144K sh	—	—	144,000
2026-03-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,581 sh	$1.60	−$2,529.6	187,375
2025-12-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,576 sh	$1.77	−$2,792.514	188,956
2025-12-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+120K sh	$1.60	+$192K	190,532
2025-09-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,576 sh	$1.81	−$2,852.56	70,532
2025-06-06	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,576 sh	$1.75	−$2,758	72,108
2025-04-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+14K sh	—	—	73,684
2025-04-01	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+84K sh	—	—	84,000
2025-03-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,808 sh	$1.87	−$3,389.638	59,684
2024-12-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,559 sh	$1.86	−$2,899.74	61,492
2024-09-05	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−6,265 sh	$2.88	−$18K	63,051
2024-04-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+69.3K sh	—	—	69,316
2024-04-01	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+291K sh	—	—	291,450

Recent filings

Accepted (ET)
Sep 104
Wapnick Pamela0001193125-26-387786
SEC(opens sec.gov)
Jun 104
Wapnick Pamela0001193125-26-265335
SEC(opens sec.gov)
Apr 34
Wapnick Pamela0001193125-26-141867
SEC(opens sec.gov)
Mar 94
Wapnick Pamela0001193125-26-098824
SEC(opens sec.gov)
Dec 84
Wapnick Pamela0001193125-25-310953
SEC(opens sec.gov)
Dec 14
Wapnick Pamela0001193125-25-304218
SEC(opens sec.gov)
Jun 94
Wapnick Pamela0000950170-25-083949
SEC(opens sec.gov)
Apr 34
Wapnick Pamela0000950170-25-050103
SEC(opens sec.gov)
Mar 74
Wapnick Pamela0000950170-25-035565
SEC(opens sec.gov)
Dec 64
Wapnick Pamela0000950170-24-134124
SEC(opens sec.gov)
Sep 64
Wapnick Pamela0000950170-24-104439
SEC(opens sec.gov)
Apr 34
Wapnick Pamela0000950170-24-041537
SEC(opens sec.gov)

Companies

Metagenomi Therapeutics, Inc.Chief Financial OfficerMGX

Address

C/O METAGENOMI THERAPEUTICS, INC. 5959 HORTON STREET, 7TH FLOOR

EMERYVILLE, CA, 94608